



Supplementary Fig. S1. Proportion of PsA patients with axial involvement achieving cDAPSA LDA/remission, MDA/VLDA and improvement of at least 50% in BASDAI score at one-year follow-up for ustekinumab and TNFi in the PsABio Italian cohort.^a

BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; cDAPSA: clinical Disease Activity index for PSoriatic Arthritis; LDA: low disease activity; MDA: minimal disease activity; TNFi: tumour necrosis factor inhibitor; UST: ustekinumab; VLDA: very low disease activity

^a PS-adjusted odds ratios and 95% confidence intervals could not be calculated due to small number of patients.